Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK56G0)

Drug Name

Bexagliflozin Drug Info

Synonyms

UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Approved	[1]
Type-2 diabetes	5A11	Phase 3	[2]

Cross-matching ID

PubChem CID: 25195624
CAS Number: CAS 1118567-05-7
TTD Drug ID: DMK56G0
VARIDT Drug ID: DR01083

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[5]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[6]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[6]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[7]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[7]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[6]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[7]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[7]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[7]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Sodium/glucose cotransporter 2 (SLC5A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[9]
Dapagliflozin	DM28UJG	Non-insulin dependent diabetes	5A11	Approved	[10]
PF-04971729	DM79VXT	Type-2 diabetes	5A11	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Canagliflozin	DMFRM1I	Non-insulin dependent diabetes	5A11	Approved	[10]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[13]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[14]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[10]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[15]
T-1095	DMGFS51	Diabetic complication	5A2Y	Discontinued in Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Sodium/glucose cotransporter 2 (SLC5A2)	OT93UUDI	SC5A2_HUMAN	Gene/Protein Processing	[3]
UDP-glucuronosyltransferase 1A9	OTPCHAFX	UD19_HUMAN	Regulation of Drug Effects	[4]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214373.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011 Apr;63(4):284-93. doi: 10.1016/j.phrs.2011.01.001. Epub 2011 Jan 5.
4	Bexagliflozin: First Approval. Drugs. 2023 Apr;83(5):447-453. doi: 10.1007/s40265-023-01848-x.
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
6	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
7	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
8	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
9	Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
10	Discovery of novel N--D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem. 2011 Jan 13;54(1):166-78. doi: 10.1021/jm101072y. Epub 2010 Dec 3.
11	Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. doi: 10.1021/jm200049r. Epub 2011 Mar 30.
12	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
13	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
14	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
15	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.